|
|
|
|
| LEADER |
01544nam a2200253 u 4500 |
| 001 |
EB002010746 |
| 003 |
EBX01000000000000001173645 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
220201 r ||| eng |
| 100 |
1 |
|
|a Ho, Chuong
|
| 245 |
0 |
0 |
|a Mohs surgery for the treatment of skin cancer
|h Elektronische Ressource
|b a review of guidelines
|c Chuong Ho, Charlene Argáez
|
| 250 |
|
|
|a Version 1.0
|
| 260 |
|
|
|a Ottawa (ON)
|b CADTH
|c 2019, March 20, 2019
|
| 300 |
|
|
|a 1 PDF file (18 pages)
|b illustration
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 700 |
1 |
|
|a Argáez, Charlene
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK546997
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Nine evidence-based guidelines were identified; two guidelines issued recommendations on basal cell carcinoma, four on squamous cell carcinoma, two on melanoma, and one on Merkel cell carcinoma. Mohs micrographic surgery (MMS) is recommended as a first-line option for high-risk primary or recurrent basal cell carcinoma. For high-risk primary or recurrent squamous cell carcinoma, MMS may be considered as one of the options, especially where tissue preservation or margin controls are challenging, or when the tumour is at a critical anatomical site
|